View Older Stories View More Recent Stories
-
Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ)
-
J&J's TREMFYA wins FDA approval for subcutaneous ulcerative colitis treatment
-
Rothschild upgrades Kenvue after Tylenol scare wipes $10 billion in market value
-
FDA issues warning letter to Johnson & Johnson (JNJ) after inspecting Janssen vaccine manufacturing facilities
-
Stifel: Electrophysiology Market Growth is Healthy
-
Guggenheim Upgrades Johnson & Johnson (JNJ) to Buy
-
CDC Panel Votes Against Requiring Prescriptions For Covid Shots - Bloomberg
-
CDC Panel Votes To End Universal Recommendation For Covid Shots - Bloomberg
-
Johnson & Johnson reports positive results from multiple myeloma study
-
Johnson & Johnson (JNJ) PT Raised to $186 at Goldman Sachs
-
Johnson & Johnson's icotrokinra outperforms rival drug in psoriasis trials
-
Guggenheim Reiterates Neutral Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) PT Raised to $195 at Wolfe Research, 'increased confidence in JNJ's upcoming talc litigation outcome'
-
Johnson & Johnson presents atrial fibrillation device study results
-
Buy this U.S. large-cap biopharma stock: JPMorgan
-
This MedTech stock is 'a strong buy under $500': Bernstein
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
Johnson & Johnson launches AI bunion surgery system in U.S.
-
Johnson & Johnson seeks FDA approval for TREMFYA joint damage claims
-
FDA grants priority review to Johnson & Johnson's TAR-200 bladder cancer drug
-
Johnson & Johnson (JNJ): EU approves Darzalex as the first licensed treatment for patients with high-risk smouldering multiple myeloma
-
Erste Group Upgrades Johnson & Johnson (JNJ) to Buy
-
Johnson & Johnson submits FDA application for psoriasis drug icotrokinra
-
Johnson & Johnson (JNJ) PT Raised to $185 at RBC Capital
-
Johnson & Johnson (JNJ) PT Raised to $190 at UBS
-
Johnson & Johnson gets FDA priority review for bladder cancer treatment
-
Johnson & Johnson (JNJ) PT Raised to $167 at Guggenheim
-
Johnson & Johnson (JNJ) PT Raised to $185 at Goldman Sachs
-
Johnson & Johnson (JNJ) PT Raised to $165 at Stifel
-
Johnson & Johnson (JNJ) Tops Q2 EPS by 9c, Beats on Revenue; Offers Strong FY25 Guidance
-
Stocks expected to have increasing option volume: MS GS BAC JNJ PNC PGR
-
Johnson & Johnson earnings preview Q2: flat print expected, tariff impact in focus
-
Johnson & Johnson (JNJ) call put ratio 1.7 calls to 1 put into quarter results
-
Johnson & Johnson (JNJ) call put ratio 1.2 calls to 1 put into quarter results
-
Wolfe Research Reiterates Outperform Rating on Johnson & Johnson (JNJ)
-
Goldman Sachs Reiterates Conviction Buy Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson submits FDA application for CAPLYTA schizophrenia use
-
Johnson & Johnson (JNJ) reports IMAAVY showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis
-
Johnson & Johnson (JNJ) says IMBRUVICA received positive CHMP opinion for the treatment of patients with previously untreated MCL
-
Johnson & Johnson (JNJ) says dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
-
Kenvue (KVUE) considers selling skin health and beauty brands, sources say - Reuters
-
Johnson & Johnson (JNJ) says bleximenib demonstrated promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
-
Johnson & Johnson (JNJ) Reports New guselkumab showing its significantly inhibits progression of joint structural damage in active psoriatic arthritis
-
Johnson & Johnson (JNJ) Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
-
Johnson & Johnson's (JNJ) DARZALEX FASPRO shows strong data
-
Johnson & Johnson (JNJ): Single infusion of CARVYKTI delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
-
Johnson & Johnson (JNJ) announces promising early results from TsAb
-
Johnson & Johnson (JNJ) FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO
-
FDA Mandates Trials For Covid Boosters For Healthy Kids, Adults - NEJM
-
Johnson & Johnson (JNJ) call put ratio 1 call to 1 put as share price down 3.1%
